No surprises Cafa,
Without the required ground and clinical work (using scientifically valid methods and analysis), OSL will get nowhere.
They're stringing shareholders along and wasting capital on "trying" to get a positive result with the NB (when none is clearly forthcoming), when OSL should be spending the capital on fulfilling the requirements as set out in the CE marking directives via. scientific studies.
At least the gullibles are happy to see a rising share price on the back of spruikers pumping the stock.
No surprises Cafa, Without the required ground and clinical work...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.015(1.39%) |
Mkt cap ! $19.95M | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.06 | $14.31K | 13.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 56 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 9552 | 1 |
View Market Depth
| Last trade - 13.05pm 31/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |